지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.1
- 수록면
- 87 - 94 (8page)
이용수
초록· 키워드
오류제보하기
Statins have been shown to be very effective and safe in numerous randomized clinical trials, and became the implacable first-line treatment against atherogenic dyslipidemia. However, even with optimal statin treatment, 60% to 80% of residual cardiovascular risk still exists. The patients with familial hypercholesterolemia which results in extremely high level of low density lipoprotein cholesterol (LDL-C) level and the patients who are intolerant or unresponsive to statins are the other hurdles of statin treatment. Recently, new classes of lipid-lowering drugs have been developed and some of them are available for the clinical practice. The pro-protein convertase subtilisin/kexintype 9 (PCSK9) inhibitor increases the expression of low density lipoprotein (LDL) receptor in hepatocytes by enhancing LDL receptor recycling. The microsomal triglyceride transport protein (MTP) inhibitor and antisense oligonucleotide against apolipoprotein B (ApoB) reduce the ApoB containing lipoprotein by blocking the hepatic very low density lipoprotein synthesis pathway. The apolipoprotein A1 (ApoA1) mimetics pursuing the beneficial effect of high density lipoprotein cholesterol and can reverse the course of atherosclerosis. ApoA1 mimetics had many controversial clinical data and need more validation in humans. The PCSK9 inhibitor recently showed promising results of significant LDL-C lowering in familial hypercholesterolemia (FH) patients from the long-term phase III trials. The MTP inhibitor and antisesnse oligonucleotide against ApoB were approved for the treatment of homozygous FH but still needs more consolidated evidences about hepatic safety such as hepatosteatosis. We would discuss the benefits and concerns of these new lipid-lowering drugs anticipating additional benefits beyond statin treatment.
목차
등록된 정보가 없습니다.
참고문헌 (42)
참고문헌 신청
노은 / 2013 / Prevalence and Management of Dyslipidemia in Korea:Korea National Health and Nutrition Examination Survey during 1998 to 2010 / Diabetes and Metabolism Journal 37(6):433~449
구보경 / 2014 / Statin for the Primary Prevention of Cardiovascular Disease in Patients with Diabetes Mellitus / Diabetes and Metabolism Journal 38(1):32~34
Lim S / 2013 / How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol / Int J Cardiol 166:8~14
Sampson UK / 2012 / Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges / Curr Atheroscler Rep 14:1~10
Hovingh GK / 2013 / Diagnosis and treatment of familial hypercholesterolaemia / Eur Heart J 34:962~971
구보경 / 2014 / Statin for the Primary Prevention of Cardiovascular Disease in Patients with Diabetes Mellitus / Diabetes and Metabolism Journal 38(1):32~34
Lim S / 2013 / How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol / Int J Cardiol 166:8~14
Sampson UK / 2012 / Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges / Curr Atheroscler Rep 14:1~10
Hovingh GK / 2013 / Diagnosis and treatment of familial hypercholesterolaemia / Eur Heart J 34:962~971
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Statin Intolerance: an Overview of the Current Status and Possible Treatment Options
지질·동맥경화학회지
2018 .01
-
Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
지질·동맥경화학회지
2019 .01
-
New Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a)
지질·동맥경화학회지
2023 .01
-
Low-Density Lipoprotein Cholesterol Level, Statin Use and Myocardial Infarction Risk in Young Adults
지질·동맥경화학회지
2022 .09
-
Efficacy and Safety of Prescription Omega-3 Fatty Acids Added to Stable Statin Therapy in Korean Patients with Type 2 Diabetes and Hypertriglyceridemia: a Randomized Controlled Trial
지질·동맥경화학회지
2019 .01
-
Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
Endocrinology and Metabolism
2021 .01
-
스타틴과 당뇨병 발생 위험
대한의사협회지
2017 .01
-
Prevention of Intra-Abdominal Adhesions Using the Combination of Mixed Solid of Poloxamer, Gelatin and Chitosan (Mediclore®) and a Statin
대한외과학회 학술대회 초록집
2021 .05
-
Myocardial Infarction, Stroke, and All-Cause Mortality according to Low-Density Lipoprotein Cholesterol Level in the Elderly, a Nationwide Study
Diabetes and Metabolism Journal
2022 .09
-
Should We Intensify Statin Management in ACS Patients with Very Low LDL Cholesterol Levels?
지질·동맥경화학회지
2019 .01
-
Pre-Treatment with Statins for Coronary Intervention: Pleiotropy of Statins or Effect of LDL-cholesterol Reduction?
Korean Circulation Journal
2016 .01
-
Intensity of Statin Treatment in Korean Patients with Acute Myocardial Infarction and Very Low LDL Cholesterol
지질·동맥경화학회지
2019 .01
-
스타틴이 총 사망률에 미치는 영향
대한내과학회지
2023 .02
-
고지혈증 치료 가이드라인
대한내과학회지
2019 .10
-
Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments
Endocrinology and Metabolism
2020 .01
-
Clinical Benefit of Statins in Korean Patients with Acute Myocardial Infarction: Experience of the Korea Acute Myocardial Infarction Registry
지질·동맥경화학회지
2020 .01
-
Mechanism, clinical consequences, and management of dyslipidemia in children with nephrotic syndrome
Childhood Kidney Diseases
2022 .06
-
Current drugs, targets, and drug delivery systems for the treatment of dyslipidemia
Journal of Pharmaceutical Investigation
2018 .05
-
Non-achievement of the Low-Density Lipoprotein Cholesterol Goal in Older Patients with Type 2 Diabetes Mellitus and a Very High Cardiovascular Disease Risk: A Multicenter Study in Vietnam
Annals of geriatric medicine and research
2021 .12
이 논문의 저자 정보
최근 본 자료
댓글(0)
0